Clinical practice value of hematological inflammation biomarkers in nasopharyngeal carcinoma

doi:10.3760/cma.j.issn.1673-422X.2019.08.010

Abstract

Abstract: Inflammation promotes tumor initiate, progress, invade and metastasize. Hematological inflammation biomarkers in nasopharyngeal carcinoma (peripheral blood neurtrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, systemic immune-inflammation index and C-creative protein) are the expressions of inflammation in the progress of nasopharyngeal carcinoma. The information of prognosis can be obtained by testing the hematological inflammation biomarkers in nasopharyngeal carcinoma patients. These biomarkers are the supplement for the current prognosis predictive indices and they can be used to guide the clinical practice, which will provide more ideas.

Key words: Nasopharyngeal neoplasms, Prognosis, Hematological inflammation biomarker

Zhou Yuanyuan, Li Jing. Clinical practice value of hematological inflammation biomarkers in nasopharyngeal carcinoma[J]. Journal of International Oncology, 2019, 46(8): 492-495.

References

［1］ Fernandes JV, Cobucci RN, Jatobá CA, et al. The role of the mediators of inflammation in cancer development［J］. Pathol Oncol Res, 2015, 21(3): 527-534. DOI: 10.1007/s12253-015-9913-z. ［2］ Oliva N, Carcole M, Beckerman M, et al. Regulation of dendrimer/dextran material performance by altered tissue microenvironment in inflammation and neoplasia［J］. Sci Transl Med, 2015, 7(272): 272ra11. DOI: 10.1126/scitranslmed.aaa1616. ［3］ Lippitz BE. Cytokine patterns in patients with cancer: a systematic review［J］. Lancet Oncol, 2013, 14(6): e218-e228. DOI: 10.1016/S1470-2045(12)70582-X. ［4］ Yao JJ, Zhu FT, Dong J, et al. Prognostic value of neutrophil-to-lymphocyte ratio in advanced nasopharyngeal carcinoma: a large institution-based cohort study from an endemic area［J］. BMC Cancer, 2019, 19(1): 37. DOI: 10.1186/s12885-018-5236-2. ［5］李晓惠, 徐冰清, 高劲, 等. 中性粒细胞与淋巴细胞比值对鼻咽癌放射敏感性及预后影响的研究［J］. 中华放射肿瘤学杂志, 2016, 25(5): 432-435. DOI: 10.3760/ema.j.issn.1004-4221.2016.05.002. ［6］ Chua ML, Tan SH, Kusumawidjaja G, et al. Neutrophil-to-lymphocyte ratio as a prognostic marker in locally advanced nasopharyngeal carcinoma: a pooled analysis of two randomised controlled trials［J］. Eur J Cancer, 2016, 67: 119-129. DOI: 10.1016/j.ejca.2016.08.006. ［7］ Sun W, Zhang L, Luo M, et al. Pretreatment hematologic markers as prognostic factors in patients with nasopharyngeal carcinoma: neutrophil-lymphocyte ratio and plateletlymphocyte ratio［J］. Head Neck, 2016, 38 Suppl 1: e1332e1340. DOI: 10.1002/hed.24224. ［8］聂冬, 王若峥, 吾甫尔, 等. 治疗前PLR与NLR在评估新疆维吾尔族鼻咽癌预后价值中的初步探讨［J］. 中国医师杂志, 2016, 18(5): 647-652. DOI: 10.3760/cma.j.issn.1008-1372.2016.05.003. ［9］ Su L, Zhang M, Zhang W, et al. Pretreatment hematologic markers as prognostic factors in patients with nasopharyngeal carcinoma［J］. Medicine (Baltimore), 2017, 96(11): e6364. DOI: 10.1097/md.0000000000006364. ［10］ Jiang W, Chen Y, Huang J, et al. Systemic immune-inflammation index predicts the clinical outcome in patients with nasopharyngeal carcinoma: a propensity score-matched analysis［J］. Oncotarget, 2017, 8(39): 66075-66086. DOI: 10.18632/oncotarget.19796. ［11］ Jiang Y, Qu S, Pan X, et al. Prognostic value of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in intensity modulated radiation therapy for nasopharyngeal carcinoma［J］. Oncology, 2018, 9(11): 9992-10004. DOI: 10.18632/oncotarget.24173. ［12］ Ye L, Oei RW, Kong F, et al. Prognostic values of hematological biomarkers in nasopharyngeal carcinoma patients treated with intensity-modulated radiotherapy［J］. Eur Arch Otorhinolaryngol, 2018, 275(5): 1309-1317. DOI: 10.1007/s00405-018-4956-x. ［13］ Hu B, Yang XR, Xu Y, et al. Systemic immune-inflammation index predicts prognosis of patients after curative resection for hepatocellular carcinoma［J］. Clin Cancer Res, 2014, 20(23): 6212-6122. DOI: 10.1158/1078-0432.CCR-14-0442. ［14］ Chen JH, Zhai ET, Yuan YJ, et al. Systemic immune-inflammation index for predicting prognosis of colorectal cancer［J］. World J Gastroenterol, 2017, 23(34): 6261-6272. DOI: 10.3748/wjg.v23.i34.6261. ［15］ Aziz MH, Sideras K, Aziz NA, et al. The systemic-immune-inflammation index independently predicts survival and recurrence in resectable pancreatic cancer and its prognostic value depends on bilirubin levels: a retrospective multicenter cohort study［J］. Ann Surg, 2019, 270(1): 139-146. DOI: 10.1097/SLA.0000000000002660. ［16］ Fest J, Ruiter R, Mulder M, et al. The systemic immune-inflammation index is associated with an increased risk of incident cancer-a population-based cohort study［J］. Int J Cancer, 2019, Inpress. DOI: 10.1002/ijc.32303. ［17］ Oei RW, Ye L, Kong F, et al. Prognostic value of inflammation-based prognostic index in patients with nasopharyngeal carcinoma: a propensity score matching study［J］. Cancer Manag Res, 2018, 10: 2785-2797. DOI: 10.2147/CMAR.S171239. ［18］ Fang Y, Xu C, Wu P, et al. Prognostic role of C-reactive protein in patients with nasopharyngeal carcinoma［J］. Medicine (Baltimore), 2017, 96(45): e8463. DOI: 10.1097/MD.0000000000008463. ［19］ Zeng YC, Wu R, Xiao YP, et al. Serum C-reactive protein predicts poor prognosis in patients with locoregionally advanced nasopharyngeal carcinoma treated with chemoradiotherapy［J］. Curr Oncol, 2015, 22(1): 20-24. DOI: 10.3747/co.22.2178. ［20］ Tang LQ, Hu DP, Chen QY, et al. Elevated highsensitivity C-reactive protein levels predict decreased survival for nasopharyngeal carcinoma patients in the intensity-modulated radiotherapy Era［J］. PLoS One, 2015, 10(4): e0122965. DOI: 10.1371/journal.pone.0122965. ［21］ Chen R, Zhou Y, Yuan Y, et al. Effect of CRP and kinetics of CRP in prognosis of nasopharyngeal carcinoma［J］. Front Oncol, 2019, 9: 89. DOI: 10.3389/fonc.2019.00089. ［22］ Chen QY, Tang QN, Tang LQ, et al. Pretreatment serum amyloid A and C-reactive protein comparing with Epstein-Barr virus DNA as prognostic indicators in patients with nasopharyngeal carcinoma: a prospective study［J］. Cancer Res Treat, 2018, 50(3): 701-711. DOI: 10.4143/crt.2017.180. ［23］ Liu X, Sun X, Liu J, et al. Preoperative C-reactive protein/albumin ratio predicts prognosis of patients after curative resection for gastric cancer［J］. Transl Oncol, 2015, 8(4): 339-345. DOI: 10.1016/j.tranon.2015.06.006. ［24］ Ishizuka M, Nagata H, Takagi K, et al. Clinical significance of the C-reactive protein to albumin ratio for survival after surgery for colorectal cancer［J］. Ann Surg Oncol, 2016, 23(3): 900-907. DOI: 10.1245/s10434-015-4948-7. ［25］ Gao N, Yang RN, Meng Z, et al. The prognostic value of C-reactive protein/albumin ratio in nasopharyngeal carcinoma: a meta-analysis［J］. Biosci Rep, 2018, 38(6): pii: BSR20180686. DOI: 10.1042/BSR20180686. ［26］ Zhang Y, Zhou GQ, Liu X, et al. Exploration and validation of C-reactive protein/albumin ratio as a novel inflammation-based prognostic marker in nasopharyngeal carcinoma［J］. J Cancer, 2016, 7(11): 1406-1412. DOI: 10.7150/jca.15401. ［27］ Tao CJ, Chen YY, Jiang F, et al. The C-reactive protein/albumin ratio is an independent prognostic factor for overall survival in patients with nasopharyngeal carcinoma receiving intensity-modulated radiotherapy［J］. J Cancer, 2016, 7(14): 2005-2011. DOI: 10.7150/jca.16210. ［28］ Wang Y, Yang L, Xia L, et al. High C-reactive protein/albumin ratio predicts unfavorable distant metastasis-free survival in nasopharyngeal carcinoma: a propensity score-matched analysis［J］. Cancer Manag Res, 2018, 10: 371-381. DOI: 10.2147/cmar.s155604. ［29］ Sun P, Chen C, Xia Y, et al. The ratio of C-reactive protein/albumin is a novel inflammatory predictor of overall survival in cisplatin-based treated patients with metastatic nasopharyngeal carcinoma［J］. Dis Markers, 2017, 2017: 6570808. DOI: 10.1155/2017/6570808. ［30］ He S, Wang Y, Chen H, et al. C-reactive protein/albumin ratio (CAR) as a prognostic factor in patients with non-metastatic nasopharyngeal carcinoma［J］. J Cancer, 2016, 7(15): 2360-2366. DOI: 10.7150/jca.16443. ［31］ Li XH, Chang H, Xu BQ, et al. An inflammatory biomarker-based nomogram to predict prognosis of patients with nasopharyngeal carcinoma: an analysis of a prospective study［J］. Cancer Med, 2016, 6(1): 310-319. DOI: 10.1002/cam4.947. ［32］ Chen C, Sun P, Dai QS, et al. The Glasgow prognostic score predicts poor survival in cisplatin-based treated patients with metastatic nasopharyngeal carcinoma［J］. PLoS One, 2014, 9(11): e112581. DOI: 10.1371/journal.pone.0112581. ［33］ Li JP, Chen SL, Liu XM, et al. A novel inflammation-based stage (Ⅰ stage) predicts overall survival of patients with nasopharyngeal carcinoma［J］. Int J Mol Sci, 2016, 17(11): pii. E1900. DOI: 10.3390/ijms17111900.

[1]	Qian Xiaotao, Shi Ziyi, Hu Ge, Wu Xiaowei. Efficacy of consolidation chemotherapy after radical radiotherapy and chemotherapy for stage Ⅲ-ⅣA esophageal squamous cell carcinoma： a real-world clinical study [J]. Journal of International Oncology, 2024, 51(6): 326-331.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun. Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer [J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Xu Fenglin, Wu Gang. Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma [J]. Journal of International Oncology, 2024, 51(6): 359-363.
[4]	Fan Zhipeng, Yu Jing, Hu Jing, Liao Zhengkai, Xu Yu, Ouyang Wen, Xie Conghua. Predictive value of changes in inflammatory markers for prognosis in patients with advanced non-small cell lung cancer treated with the first-line immunotherapy plus chemotherapy [J]. Journal of International Oncology, 2024, 51(5): 257-266.
[5]	Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin. Study on the clinical relationship between inflammatory burden index and gastric cancer [J]. Journal of International Oncology, 2024, 51(5): 274-279.
[6]	Liu Pingping, He Xuefang, Zhang Yi, Yang Xu, Zhang Shanshan, Ji Yifei. Risk factors of postoperative recurrence in patients with primary brain glioma and prediction model construction [J]. Journal of International Oncology, 2024, 51(4): 193-197.
[7]	Wan Fang, Yang Gang, Li Rui, Wan Qijing. Expression levels and clinical significance of serum miR-497 and miR-383 in patients with esophageal cancer [J]. Journal of International Oncology, 2024, 51(4): 204-209.
[8]	Yao Yixin, Shen Yulin. Predictive value of serum SOCS3 and TXNIP levels for the prognosis of patients with hepatocellular carcinoma treated with TACE [J]. Journal of International Oncology, 2024, 51(4): 217-222.
[9]	Sun Weiwei, Yao Xuemin, Wang Pengjian, Wang Jing, Jia Jinghao. Exploration of prognostic factors and nomogram construction for advanced non-small cell lung cancer treated with immunotherapy based on hematologic indexes [J]. Journal of International Oncology, 2024, 51(3): 143-150.
[10]	Liu Yulan, Jing Haiyan, Sun Jing, Song Wei, Sha Dan. Advances in predicting efficacy and prognostic markers of immunotherapy for gastric cancer [J]. Journal of International Oncology, 2024, 51(3): 175-180.
[11]	Peng Qin, Cai Yuting, Wang Wei. Advances on KPNA2 in liver cancer [J]. Journal of International Oncology, 2024, 51(3): 181-185.
[12]	Chen Boguang, Wang Sugui, Zhang Yongjie. Role of serum cholinesterase and inflammatory markers in the prognosis of stage ⅠA -ⅢA breast cancer [J]. Journal of International Oncology, 2024, 51(2): 73-82.
[13]	Jin Xudong, Chen Zhongjian, Mao Weimin. Research progress on the role of MTAP in malignant mesothelioma [J]. Journal of International Oncology, 2024, 51(2): 99-104.
[14]	Huang Zhen, Chen Yongshun. Research progress of circulating tumor DNA in the diagnosis and treatment of hepatocellular carcinoma [J]. Journal of International Oncology, 2024, 51(1): 59-64.
[15]	Wang Xiao, Li Ying, Luo Yujie, Jin Shu. Study on the prognostic value of serological indicators for nasopharyngeal carcinoma based on nomogram model [J]. Journal of International Oncology, 2023, 50(8): 463-469.